Your browser doesn't support javascript.
loading
Enhancing probiotic impact: engineering Saccharomyces boulardii for optimal acetic acid production and gastric passage tolerance.
de Carvalho, Bruna Trindade; Subotic, Ana; Vandecruys, Paul; Deleu, Sara; Vermeire, Séverine; Thevelein, Johan M.
Afiliación
  • de Carvalho BT; NovelYeast bv, Bio-Incubator BIO4, Leuven-Heverlee, Belgium.
  • Subotic A; NovelYeast bv, Bio-Incubator BIO4, Leuven-Heverlee, Belgium.
  • Vandecruys P; Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, Leuven-Heverlee, Belgium.
  • Deleu S; Department of Chronic Diseases, Metabolism & Ageing (CHROMETA), KU Leuven, Leuven, Belgium.
  • Vermeire S; Department of Chronic Diseases, Metabolism & Ageing (CHROMETA), KU Leuven, Leuven, Belgium.
  • Thevelein JM; NovelYeast bv, Bio-Incubator BIO4, Leuven-Heverlee, Belgium.
Appl Environ Microbiol ; 90(6): e0032524, 2024 Jun 18.
Article en En | MEDLINE | ID: mdl-38752748
ABSTRACT
Saccharomyces boulardii has been a subject of growing interest due to its potential as a probiotic microorganism with applications in gastrointestinal health, but the molecular cause for its probiotic potency has remained elusive. The recent discovery that S. boulardii contains unique mutations causing high acetic acid accumulation and inhibition of bacterial growth provides a possible clue. The natural S. boulardii isolates Sb.P and Sb.A are homozygous for the recessive mutation whi2S270* and accumulate unusually high amounts of acetic acid, which strongly inhibit bacterial growth. However, the homozygous whi2S270* mutation also leads to acetic acid sensitivity and acid sensitivity in general. In the present study, we have constructed a new S. boulardii strain, derived from the widely therapeutically used CMCN I-745 strain (isolated from the pharmaceutical product Enterol), producing even higher levels of acetic acid while keeping the same tolerance toward low pH as the parent Enterol (ENT) strain. This newly engineered strain, named ENT3, has a homozygous deletion of ACH1 and strong overexpression of ALD4. It is also able to accumulate much higher acetic acid concentrations when growing on low glucose levels, in contrast to the ENT wild-type and Sb.P strains. Moreover, we show the antimicrobial capacity of ENT3 against gut pathogens in vitro and observed that higher acetic acid production might correlate with better persistence in the gut in healthy mice. These findings underscore the possible role of the unique acetic acid production and its potential for improvement of the probiotic action of S. boulardii.IMPORTANCESuperior variants of the probiotic yeast Saccharomyces boulardii produce high levels of acetic acid, which inhibit the growth of bacterial pathogens. However, these strains also show increased acid sensitivity, which can compromise the viability of the cells during their passage through the stomach. In this work, we have developed by genetic engineering a variant of Saccharomyces boulardii that produces even higher levels of acetic acid and does not show enhanced acid sensitivity. We also show that the S. boulardii yeasts with higher acetic acid production persist longer in the gut, in agreement with a previous work indicating competition between probiotic yeast and bacteria for residence in the gut.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ácido Acético / Probióticos / Saccharomyces boulardii Límite: Animals Idioma: En Revista: Appl Environ Microbiol Año: 2024 Tipo del documento: Article País de afiliación: Bélgica

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ácido Acético / Probióticos / Saccharomyces boulardii Límite: Animals Idioma: En Revista: Appl Environ Microbiol Año: 2024 Tipo del documento: Article País de afiliación: Bélgica